MeiraGTx Holdings plc (NASDAQ:MGTX) CFO Richard Giroux Sells 24,000 Shares

MeiraGTx Holdings plc (NASDAQ:MGTX - Get Free Report) CFO Richard Giroux sold 24,000 shares of the business's stock in a transaction dated Tuesday, April 22nd. The shares were sold at an average price of $6.00, for a total value of $144,000.00. Following the completion of the sale, the chief financial officer now directly owns 882,494 shares of the company's stock, valued at approximately $5,294,964. This represents a 2.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

MeiraGTx Stock Performance

MGTX stock traded up $0.62 during midday trading on Tuesday, reaching $6.27. The company had a trading volume of 809,500 shares, compared to its average volume of 320,718. The company has a quick ratio of 2.34, a current ratio of 2.34 and a debt-to-equity ratio of 0.86. The stock has a 50 day moving average price of $6.55 and a 200 day moving average price of $6.25. MeiraGTx Holdings plc has a fifty-two week low of $3.85 and a fifty-two week high of $8.75. The firm has a market capitalization of $494.42 million, a PE ratio of -5.18, a P/E/G ratio of 0.37 and a beta of 1.21.

MeiraGTx (NASDAQ:MGTX - Get Free Report) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The company had revenue of $21.39 million during the quarter, compared to the consensus estimate of $1.50 million. MeiraGTx had a negative return on equity of 146.38% and a negative net margin of 633.05%. Analysts anticipate that MeiraGTx Holdings plc will post -1.48 earnings per share for the current year.

Hedge Funds Weigh In On MeiraGTx

Several institutional investors have recently modified their holdings of MGTX. State Street Corp lifted its position in MeiraGTx by 0.9% in the 3rd quarter. State Street Corp now owns 574,727 shares of the company's stock valued at $2,397,000 after purchasing an additional 5,251 shares during the last quarter. Barclays PLC boosted its position in shares of MeiraGTx by 107.1% during the third quarter. Barclays PLC now owns 147,827 shares of the company's stock worth $618,000 after buying an additional 76,437 shares during the period. Garden State Investment Advisory Services LLC acquired a new stake in MeiraGTx in the 3rd quarter valued at approximately $1,636,000. JPMorgan Chase & Co. raised its stake in MeiraGTx by 1.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 342,667 shares of the company's stock valued at $1,429,000 after acquiring an additional 4,186 shares in the last quarter. Finally, SG Americas Securities LLC grew its stake in shares of MeiraGTx by 13.3% in the fourth quarter. SG Americas Securities LLC now owns 22,240 shares of the company's stock worth $135,000 after purchasing an additional 2,617 shares in the last quarter. Institutional investors own 67.48% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Chardan Capital reiterated a "buy" rating and issued a $36.00 target price on shares of MeiraGTx in a research report on Monday, February 24th. Royal Bank of Canada boosted their target price on shares of MeiraGTx from $11.00 to $13.00 and gave the company an "outperform" rating in a research note on Monday, March 17th.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.